Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
Transfusion2020Vol. 60(12), pp. 2938–2951
Citations Over TimeTop 10% of 2020 papers
Silvano Wendel, José Mauro Kutner, Rafael Rahal Guaragna Machado, Rita Fontão‐Wendel, Carolina Bonet Bub, Roberta Fachini, Ana Paula Hitomi Yokoyama, Gabriela Candelária, Araci Massami Sakashita, Ruth Achkar, Nelson Hamerschlak, Patrícia Scuracchio, Marcelo Amaral, Mirian Dal Ben, Danielle Bastos Araújo, Camila Pereira Soares, Anamaria A. Camargo, Esper G. Kallás, Edison Luíz Durigon, Luiz F. L. Reis, Luiz Vicente Rizzo
Abstract
RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
Related Papers
- → Racing Towards the Development of Diagnostics for a Novel Coronavirus (2019-nCoV)(2020)32 cited
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management(2022)21 cited
- → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited